Abstract: Methods, systems etc., for predicting and/or consistently obtaining uniform biopolymer compositions by blending a plurality of input biopolymer compositions with different molecular weight distributions, the blending based on concentration data as a function of molecular weight for the plurality of input biopolymer compositions.

Abstract: Fluid collection/injection device comprises a body having a front end, a back end, and a main hollow section arranged between the front and back ends and a needle hub securing section arranged on the front end and being structured and arranged to receive therein a needle member. The fluid collection/injection device is structured and arranged to utilize at least an operational mode, an operational mode, and a post-use mode. In the installation mode, the needle member is coupled to the body via the needle hub securing section. In the operational mode, fluid passes through the needle member and into or out of a receptacle inserted into the main hollow section.

Abstract: Modular mammalian body implantable fluid flow influencing device, comprising: docking unit having receiving surface, distal and proximal ends, proximal guide hole. Functional unit having docking surface shaped to mate with receiving surface, distal and proximal ends. Control wire extends from proximal end of functional unit then goes through guide hold then extends proximally away from docking unit. Functional and docking units are dimensioned and shaped to be deliverable to an implantation site via catheter. Functional unit has docked configuration in which docking surface mates with receiving surface of docking unit and undocked configuration in which docking surface is unmated with and spaced apart from receiving surface of docking unit. Functional unit moveable at implantation site between undocked and docked configurations via movement of control wire. Functional unit moveable into docked configuration by pulling control wire, and moveable from into undocked configuration by pushing control wire.

Abstract: A light emitting type capsule treatment tool for irradiating light with a specific wavelength required for photoimmunotherapy, includes a power receiving coil, a magnetic member, a light emitting member and a capsule. The power receiving coil is formed by winding a conductive wire and configured to receive electric power supplied from an external transmission antenna via a magnetic flux. The magnetic member is placed on an inner circumference of the power receiving coil. The light emitting member is configured to be supplied with electric power from the power receiving coil and to emit the light with the specific wavelength. The capsule houses the power receiving coil, the magnetic member and the light emitting member.

Abstract: A surface acoustic wave (SAW) performs a rapid, label-free detection of biological species. Biosensing and detection of multiple analytes multiplexed by an array of sensing lanes is configured to enable bio-amplification using engineered DNA encoded libraries as the probe through a phage display procedure to enhance specificity, capture statistics for the detection, screening and analyzing of the analyte in vitro. A biochemical formulation minimizes the limit of detection (LOD) at a threshold magnitude on the order of a femtomolar concentration. Additional enhancement of the apparatus is achieved by use of an analog front end to amplify biochemical events.

Abstract: A method and system for detecting glucose in a biological sample is disclosed. This includes illuminating a biological sample with a light source, collecting transmitted, transflected or reflected light from the sample with a detector, generating spectral data of one or more components in the sample other than glucose in a spectral data analysis device, and analyzing the spectral data of the one or more components, sufficient to provide a glucose measurement from the spectral data of the one or more components other than glucose with the spectral data analysis device.

Abstract: The disclosure relates to antibody conjugates comprising an antibody linked to a polynucleotide, aptamer conjugates comprising an aptamer linked to a polynucleotide, and methods for detecting a marker or several markers in a sample by using said antibody and aptamer conjugates. The present disclosure also relates to microfluidics devices for detecting markers in a sample. The present disclosure further relates to methods for detecting a microorganism or several microorganisms in a sample and a microfluidics device to be used to detect such microorganisms.

Abstract: The disclosure relates to antibody conjugates or aptamer conjugates comprising an antibody linked to a lipid vesicle comprising a detectable label, methods for detecting a marker or several markers in a sample by using said antibody and aptamer conjugates. The present disclosure further relates to microfluidics devices to detect one or more markers in a sample by using said antibody and aptamer conjugates.

Abstract: Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are disclosed. Methods and systems for removing or reducing the amount of endotoxins from a starting fucan composition are also disclosed.

Abstract: The illustrated embodiments of the invention include an automated method of assaying a viral and antibody analyte in a sample in a portable, handheld microfluidic reader having a SAW detector with a minimal mass sensitivity limitation. The automated method includes the steps of automatically performing the assay with the SAW detector with enhanced sensitivity as in Optikus I, but also includes the steps of automatically disposing a second portion of the sample on a microarray, selectively automatically probing the second portion of the sample for antibodies corresponding to the at least one selected virus using the microarray, and automatically reading the microarray using a fluorescent camera to identify antibodies in the second portion of the sample.

Abstract: A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.

Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.

Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.

Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.

Abstract: The disclosure relates to a Field Effect Transistor comprising a chelator or derivatized chelator, a device for detecting a marker in a sample comprising said sensor, a method for detecting metal ions in a sample comprising said sensor or device and a sensor and method for detecting a marker in a sample.

Abstract: A rectal injection device and a method of operating the same. In one embodiment, the device includes: (1) a body having a handle, (2) a suction system associated with the body, (3) a trigger associated with the handle, (4) a pod coupled to the body via a neck and (5) multiple suction ports associated with the pod, each of the multiple suction ports configured to receive a ligation band thereabout, the suction system configured to provide a suction to the multiple suction ports to draw tissue thereinto, the pod configured to deploy the ligation bands upon activation of the trigger.

Abstract: A docking unit for use in a modular mammalian body implantable device. The docketing unit comprising an elongated body. The body has: a longitudinal axis, at least one receiving surface extending parallel to the longitudinal axis, a distal end and a proximal end, and at least one proximal guide hole. Each receiving surface has at least one proximal guide hole associated therewith. The docking unit is dimensioned and shaped to be deliverable to an implantation site within a conduit of a conduit system of the mammalian body via a catheter.

Abstract: Systems and methods are disclosed for non-invasively measuring blood glucose levels in a biological sample based on spectral data. This includes utilizing at least one light source configured to strike a target area of a sample, utilizing at least one light filter positioned to receive light transmitted through the target area from the at least one light source, utilizing at least one light detector positioned to receive light from the at least one light source and filtered by the at least one light filter, and to generate an output signal, having a time dependent current, which is indicative of the power of light detected, receiving the output signal from the at least one light detector with a processor and based on the received output signal, calculating the attenuance attributable to blood in a sample with a signal-to-noise ratio of at least 20-to-1; and determining a blood glucose level.